Please login to the form below

Not currently logged in
Email:
Password:

Shire backs campaign for ADHD support

Ireland-based pharmaceutical company Shire is supporting a European campaign to increase awareness and support for ADHD in schools as part of ADHD Awareness Week

Ireland-based pharmaceutical company Shire is supporting a European campaign to increase awareness and support for attention deficit hyperactivity disorder (ADHD) in schools as part of ADHD Awareness Week.

Stakeholders in ADHD working in policy, education and advocacy across Europe discussed methods to improve understanding and acceptance of the condition at a meeting held in Brussels, Belgium.

Delegates agreed the relationship between parents and teachers was integral to the success of any support plan and advised on four aims to help achieve their goal:

• More services and tools to help parents and teachers work together to manage the needs of a child with ADHD in the school setting effectively
• Better ADHD education for teachers to help them identify and manage the condition
• More support networks to help parents and patients with ADHD
• Greater recognition and prioritisation of ADHD in health services to improve diagnosis and management.

As part of the call for improved action, Shire, in collaboration with not-for-profit organisation ADHD Europe, launched the ADHD Partnership Support Pack - an online toolkit to help parents, carers and teachers support children with ADHD.

ADHD has an estimated global cost of $31.5bn a year, according to Shire.

28th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics